



#### Locations

Mississauga, Ontario  
Burnaby, British Columbia

#### Staff

Burnaby – Approximately 200  
Mississauga – Approximately 175  
Field and Remote employees across  
the country – Approximately 200

#### Key Functions

##### Burnaby

- Research

##### Mississauga

- Clinical Development & Scientific Affairs
- Commercial Operations
- Administrative Functions

#### Address/Phone

Amgen Canada  
6775 Financial Drive  
Mississauga, Ontario  
Canada  
L5N 0A4  
(800) 665 4273

Amgen British Columbia  
7990 Enterprise Street  
Burnaby, British Columbia  
Canada  
V5A 1V7  
(604) 676 8300

## About Amgen Canada

### Our Mission: To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines provide large clinical benefits in addressing serious diseases. And we believe these medicines not only help patients, but also help reduce the social and economic burden of disease in society.

Amgen serves patients throughout Canada by delivering vital medicines to them. In addition, Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government and patient organizations. Today, tens of thousands of Canadians use Amgen medicines every year, and thousands more are enrolling in Amgen clinical studies that deliver the next generation of innovation.

#### CLINICAL TRIALS

Amgen Canada conducts a significant number of clinical trials with leading academic research institutions, hospitals, and clinics throughout Canada. Amgen Canada's Development Operations team, working with colleagues around the world, participates in Amgen global clinical programs spanning phases 1-4 in oncology, hematology, inflammation, bone health, cardiology, metabolic disorders and neurology. Since 1994, more than 18,000 Canadian subjects have been enrolled in the Amgen clinical trials. Currently, over 600 subjects are enrolled in the 38 active trials at approximately 180 centres across Canada. A list of Amgen's clinical trials can be found on [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## AMGEN MEDICINES AVAILABLE IN CANADA

AMJEVITA™ (adalimumab-atto)  
Aranesp® (darbepoetin alfa)  
AVSOLA™ (infliximab-axxq)  
BLINCYTO® (blinatumomab)  
Enbrel® (etanercept)  
EVENITY® (romosozumab-aqqg)  
KANJINTI® (trastuzumab-anns)  
KYPROLIS® (carfilzomib)  
LUMAKRAS™ (sotorasib)  
MVASI® (bevacizumab-awwb)  
Neulasta® (pegfilgrastim)  
NEUPOGEN® (filgrastim)  
Nplate® (romiplostim)  
Otezla® (apremilast)  
Prolia® (denosumab)  
Repatha® (evolocumab)  
RIABNI™ (rituximab-arrx)  
Sensipar® (cinacalcet)  
Vectibix® (panitumumab)  
WEZLANA™ (ustekinumab)  
XGEVA® (denosumab)

### Facebook

@amgencanada

### Instagram

@amgencanada

### LinkedIn

/amgen

### Twitter

@amgencanadagm

### YouTube

@amgeninternational

## RESEARCH & DEVELOPMENT

Named one of Canada's Top 100 R&D spenders in 2018, Amgen Canada is committed to furthering the innovative research sector in Canada. On an annual basis, Amgen invests approximately CAD \$70 million into R&D in Canada, such as advisory boards, congresses, and publications—and on building research infrastructure in Canada. Amgen's Canadian research facility in Burnaby, British Columbia, plays an important role in contributing to the company's legacy as a global leader in the discovery of early-stage protein-based therapeutic candidates.

## COMMUNITY INVOLVEMENT

Winner of the BIOTECCanada Gold Leaf Award and the Mississauga Board of Trade Award in recognition of the company's contribution to communities, Amgen Canada is proud to contribute to many philanthropic efforts in the community.

Amgen is committed to raising the value of science literacy in the community; attracting bright young minds into the field of science by helping educators to teach more effectively; and improving access to science resources for teachers, students and the community at large. Amgen Canada has been a National Visionary Donor of [Let's Talk Science](#) for over 10 years, driving awareness of STEM education, offering volunteer time and supporting the development and release of research reports which highlight the importance of science learning for students, parents, teachers and the economy.

Amgen also dedicates substantial resources to strengthen and enrich the community where staff live and work supporting [Big Brothers Big Sisters](#), [Start2Finish](#), and acting as a National Health Partner of the Advanced Coronary Treatment ([ACT](#)) Foundation of Canada.

Further, as a leading member of the biotechnology sector, Amgen funds various members within this community including an Amgen Canada Fellowship in Biotechnology at The University of Toronto Mississauga (UTM) Masters of Biotechnology program.

Four Amgen Foundation global programs are now reaching teachers and students in Canada: the [Amgen Scholars Program](#) through the University of Toronto, the [Amgen Biotech Experience Canada](#) through the University of Toronto Mississauga (UTM), [LabXchange](#), a science learning digital platform developed in partnership with Harvard University and is the exclusive sponsor of [biology content at the Khan Academy](#), a free, online learning website.

Amgen also supports numerous education initiatives in partnership with patient groups—initiatives that help Canadian patients and caregivers through their cancer journey and in navigating their treatment landscape be it in bone health, cardiovascular disease, kidney disease or autoimmune disorders. Amgen is also an active member of BIOTECCanada and Innovative Medicines Canada.

